554 related articles for article (PubMed ID: 29192647)
21. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.
Noh BJ; Kwak JY; Eom DW
BMC Cancer; 2020 Jan; 20(1):58. PubMed ID: 31992245
[TBL] [Abstract][Full Text] [Related]
22. Low PD-1 Expression in Cytotoxic CD8
Mazzaschi G; Madeddu D; Falco A; Bocchialini G; Goldoni M; Sogni F; Armani G; Lagrasta CA; Lorusso B; Mangiaracina C; Vilella R; Frati C; Alfieri R; Ampollini L; Veneziani M; Silini EM; Ardizzoni A; Urbanek K; Aversa F; Quaini F; Tiseo M
Clin Cancer Res; 2018 Jan; 24(2):407-419. PubMed ID: 29074606
[No Abstract] [Full Text] [Related]
23. Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes.
Shurell E; Singh AS; Crompton JG; Jensen S; Li Y; Dry S; Nelson S; Chmielowski B; Bernthal N; Federman N; Tumeh P; Eilber FC
Oncotarget; 2016 Sep; 7(39):64300-64308. PubMed ID: 27588404
[TBL] [Abstract][Full Text] [Related]
24. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
[TBL] [Abstract][Full Text] [Related]
25. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells.
Goc J; Germain C; Vo-Bourgais TK; Lupo A; Klein C; Knockaert S; de Chaisemartin L; Ouakrim H; Becht E; Alifano M; Validire P; Remark R; Hammond SA; Cremer I; Damotte D; Fridman WH; Sautès-Fridman C; Dieu-Nosjean MC
Cancer Res; 2014 Feb; 74(3):705-15. PubMed ID: 24366885
[TBL] [Abstract][Full Text] [Related]
26. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
[TBL] [Abstract][Full Text] [Related]
27. Programmed Cell Death Ligand-1 (PDL-1) Correlates With Tumor Infiltration by Immune Cells and Represents a Promising Target for Immunotherapy in Endometrial Cancer.
Hecking T; Thiesler T; Halbe J; Otten L; Recker F; Gevensleben H; Müller T; Schiller C; Egger EK; Fimmers R; Stope MB; Kristiansen G; Mustea A
Anticancer Res; 2022 Mar; 42(3):1367-1376. PubMed ID: 35220229
[TBL] [Abstract][Full Text] [Related]
28. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
29. Immune checkpoint status and tumor microenvironment in vulvar squamous cell carcinoma.
Cocks M; Chaux A; Jenson EG; Miller JA; Rodriguez Pena MDC; Tregnago AC; Taheri D; Eich ML; Sharma R; Vang R; Netto GJ
Virchows Arch; 2020 Jul; 477(1):93-102. PubMed ID: 31993774
[TBL] [Abstract][Full Text] [Related]
30. Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients.
Kirilovsky A; Marliot F; El Sissy C; Haicheur N; Galon J; Pagès F
Int Immunol; 2016 Aug; 28(8):373-82. PubMed ID: 27121213
[TBL] [Abstract][Full Text] [Related]
31. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
[TBL] [Abstract][Full Text] [Related]
33. Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.
Jesinghaus M; Steiger K; Slotta-Huspenina J; Drecoll E; Pfarr N; Meyer P; Konukiewitz B; Bettstetter M; Wieczorek K; Ott K; Feith M; Langer R; Weichert W; Specht K; Boxberg M
Oncotarget; 2017 Jul; 8(29):46756-46768. PubMed ID: 28657901
[TBL] [Abstract][Full Text] [Related]
34. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
Lyu X; Wang P; Qiao Q; Jiang Y
BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
[TBL] [Abstract][Full Text] [Related]
35. Tumor-Infiltrating Immune Cells and PD-L1 as Prognostic Biomarkers in Primary Esophageal Small Cell Carcinoma.
Wu X; Ke X; Ni Y; Kuang L; Zhang F; Lin Y; Lin W; Xiong X; Huang H; Lin X; Zhang H
J Immunol Res; 2020; 2020():8884683. PubMed ID: 33457428
[TBL] [Abstract][Full Text] [Related]
36. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
[TBL] [Abstract][Full Text] [Related]
37. New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression.
Gullo I; Oliveira P; Athelogou M; Gonçalves G; Pinto ML; Carvalho J; Valente A; Pinheiro H; Andrade S; Almeida GM; Huss R; Das K; Tan P; Machado JC; Oliveira C; Carneiro F
Gastric Cancer; 2019 Jan; 22(1):77-90. PubMed ID: 29779068
[TBL] [Abstract][Full Text] [Related]
38. The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes.
Bonanno L; Pavan A; Dieci MV; Di Liso E; Schiavon M; Comacchio G; Attili I; Pasello G; Calabrese F; Rea F; Favaretto A; Rugge M; Guarneri V; Fassan M; Conte PF
Eur J Cancer; 2018 Sep; 101():191-200. PubMed ID: 30077124
[TBL] [Abstract][Full Text] [Related]
39. Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response.
Hijazi A; Antoniotti C; Cremolini C; Galon J
Oncoimmunology; 2023; 12(1):2243169. PubMed ID: 37554310
[TBL] [Abstract][Full Text] [Related]
40. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
